{"anticipatedPostingDate":"2010-06","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of \\>100 cells/μl 14 days after infusion with \\<5% donor T and B cells in the mononuclear population.","groups":[{"description":"Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.","id":"OG000","title":"Patients Treated With Natural Killer Cells"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 14","title":"Number of Patients Exhibiting Natural Killer Cell Expansion","type":"PRIMARY","unitOfMeasure":"Participants"}